TRANSGENE

Personalized cancer vaccines are emerging as a transformative approach in oncology, with BioNTech, Moderna, and myNEO Therapeutics leading development using mRNA technology refined during the COVID-19 pandemic.

Transgene's TG4050 demonstrated a strong clinical proof of principle in adjuvant head and neck cancer, with all 16 patients remaining disease-free after 24.1 months.

TG4050, an individualized immunotherapy, demonstrates 100% disease-free survival at 24.1 months in head and neck cancer patients after standard adjuvant therapy.

TG4050, an individualized immunotherapy, demonstrates a 100% disease-free rate in head and neck cancer patients after a median follow-up of 24.1 months.

A Phase I trial of TG4050 in head and neck cancer showed that all patients treated with the vaccine after standard care remained disease-free after 24.1 months.

Transgene's share price plummeted following the announcement of its TG4001 Phase II trial failure for treating cervical and anogenital cancers.

Transgene's TG4001 in combination with avelumab did not meet the primary endpoint of improved progression-free survival in a Phase 2 trial.

Transgene's TG4050, an individualized immunotherapy for head and neck cancer, shows promising Phase I data with a 24-month follow-up to be presented in Q4 2024.

Transgene has enrolled the first patient in the Phase II portion of its randomized Phase I/II trial evaluating TG4050, an individualized therapeutic cancer vaccine for head and neck cancer treatment.